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wherein R1 is o-chlorophenyl, o-nitrophenyl, 2,4- or

2,6-dich1orophenyl, 4-pyridyl, 3-pyridyl, Z-pyridyl, or
2-quinolyl, and R2 is hydrogen, m- or p-tri?uoromethyl,
m-chloro-p-?uoro, p-methyl, p-ethyl, m- or p-chloro,

m-nitro, p-bromo, p-tluoro, or p-COOR3, wherein R3 is
lower alkyl of 1 to 4 carbon atoms. The compositions
are administered to mammals in an amount to provide a

dosage amount ranging from about 30 mg/kg to 300
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disubstituted quaternary carbon group (barbiturates,
hydantoins, succinimides, oxazolidinediones) or closely
related structure (primidone). On the other hand, the

TRIAZOLINE ANTICONVULSANT COMPOUNDS
AND COMPOSITIONS

dicarboximide function, which contributes to the inher
ent hypnotic and sedative activity of the barbiturates
and related compounds, is absent in the triazolines.

CROSS REFERENCE TO RELATED

APPLICATIONS

Triazolines including A2-1,2,3-triazolines, are known
This application is a division of Ser. No. 629,554, ?led
to some extent in the prior art, through applicant’s own
July 10, 1984, now US. Pat. No. 4,618,681, dated Oct.
publications of work in this area. None of the triazo
21, 1986, which in turn is a continuation-in-part of Ser.
No. 476,792, ?led Mar. 18, 1983, now Us. Pat. No. 1° lines, however, has been suggested heretofore for use as
anticonvulsants.
4,511,572, dated Apr. 16, 1985.
As indicated, the present applicant has published a
TECHNICAL FIELD
number of papers involving her work on triazolines.
The following publications discuss primarily the use of
This invention relates to A2-1,2,3-triazolines and their
use as a new and novel class of anticonvulsant drugs,
and more particularly relates to certain additional new

triazolines as intermediates in providing a route for the

A2-1,2,3-triazolines, their methods of preparation, and

(Kadaba, P. K., and Triplett, J. “Heterocycles, An In

compositions for their use in the treatment of convul
sive disorders.

synthesis of certain anilinopyridazines and pyrazoles,
ternational Journal for Reviews and Communications in
20

BACKGROUND ART
Studies over the past 15 years suggest that the pre

vailing rate of epilepsy in the United States is between 5
and 20 per 1000, and recent estimates drawn from popu

lation surveys indicate that the higher rates are closer to 25
the true prevalence. This means that 1 to 4 million
Americans suffer from some form of epilepsy. For cer

tain types of seizures there are no speci?c drugs avail
able; for seizures that are controlled with currently
available therapy, a new drug may allow a reduction in 30

the toxic side effects. Despite these facts, between 1960
and 1974, no new anticonvulsant drug was marketed in

the United States (with the exception of diazepam,
which was marketed primarily as a minor tranquilizer)

Heterocyclic Chemistry,” Vol. 9, No. 3, 1978, pp.
243-246) and triazoles (Kadaba, P. K. “Syntheses, In
ternational Journal of Methods in Synthetic Organic
Chemistry,” No. 9: September, 1978, pp. 694-695.)
The following publications describe the results of
screening or evaluation of triazolines for pesticide and
herbicide properties. (Kadaba, P. K., “Pestic. Sci.,”
1974, 5, pp. 255-258.) (Kadaba, P. K., “Journal of Phar
maceutical Sciences,” Vol. 59, No. 8, 1970, pp.

1190-91.)

The following publications primarily describe proce
dures for the production of triazolines through cycload
dition of diazomethane to Schiff bases and solvent ef
fects on this reaction as well as steric effects. (Kadaba,

P. K., and Edwards, J. “Journal of Organic Chemistry,

(Vida, J. A. “Anticonvulsants,” Academic Press, New 35 26, 1961, pp. 2331-2335.) (Kadaba, P. K., “Tetrahedron,
Vol. 22, 1966, pp. 2453-2460.) (Kadaba, P. K., and Fan
York, 1977). However, since the approval of carbamaz
nin, N., “Journal of Heterocyclic Chemistry,” 4, 1967,
epine in 1974 and clonazepam in 1975, and sodium di
pp. 301-304.) (Kadaba, P. K., “Journal of Heterocyclic
propylacetate, eterobarb, mexiletine and others in
1977-1978, there has been a resurgence of interest in the

development of better anticonvulsant drugs for the
management of epilepsy. Also responsible for this re
newed interest is the establishment of the Anticonvul

sant Screening Project of the Antiepileptic Drug De
velopment (ADD) Program of NINCDS (National
Institute of Neurological and Communicative Disorders
and Stroke) of NIH, in January, 1975.
In recent years hundreds of different heterocyclic
compounds have been synthesized and screened for
anticonvulsant activity. These include mostly ?ve and
six membered ring systems containing up to three or
four heteroatoms and seven membered ring systems

Chemistry, 6, 1969, pp. 587-589.) (Kadaba, P. K. “Tet
rahedron, Vol. 25, 1969, pp. 3053-3066.) (Kadaba, P.
K., “Synthesis, International Journal of Methods in
Synthetic Organic Chemistry, No. 2: February, 1973,
pp. 71-84.) (Kadaba, P. K., “Journal of Heterocyclic
Chemistry, 12, 1975, pp. 143-146.) (Kadaba, P. K.,
“Journal of Heterocyclic Chemistry, 13, 1976, pp.

1153-54.)

In none of these publications, however, is there any

disclosure of use of any of the 1,2,3 triazoline com
pounds as anticonvulsants.

SUMMARY OF THE INVENTION
It is accordingly one object of the present invention
ing heterocycles, a considerable amount of work has
to provide certain triazolines as anticonvulsant drugs.
been done in the areas of ?ve membered rings bearing
A further object of the present invention is to provide
55
one or two nitrogen atoms.
several new A2-1,2,3-triazolines and methods for their
Five membered rings with 3 or 4 nitrogen atoms that
use in the treatment of convulsive disorders.
have been investigated, include mostly, 1,2,4-triazoles
A still further object of the present invention is to
and some tetrazoles. Very little has been done on 1,2,3
provide anticonvulsant compositions containing as the
triazoles (POPP, F. D., In “Anticonvulsants,” J. A.
Vida, Ed. Academic Press, New York, 1977). The liter 60 essential ingredient certain A2-1,2,3-triazo1ines and use
of these triazolines as antiepileptic drugs in the treat
ature indicates that to date there are no references to
ment of convulsive disorders such as epilepsy.
any published work relating to studies on the anticon
Other objects and advantages of the present invention
vulsant activity of triazolines.
will become apparent as the description thereof pro
The 1,2,3-triazolines are a novel group of anticonvul

related to the diazepines. Among the nitrogen contain

sant compounds because their heterocyclic ring system 65 ceeds.
In satisfaction of the foregoing objects and advan
tages,
there is provided by this invention anticonvulsant
drugs. The presently marketed antiepileptic drugs, for
is different from that of conventional anticonvulsant

the major part, have a dicarboximide function and/or a

compositions comprising as the active ingredient, a

3
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In a further aspect of the present invention, new com

‘ compound selected from those of the following formu
lae:

pounds are provided which have anticonvulsant activ
ity and which are of the following general formulae:

Wherein R1 is o-chlorophenyl, o-nitrophenyl, 2,4- or

In the above formulae, R1 is 2-pyridyl, 3-pyridyl,
4-pyridyl, ortho-chlorophenyl, or ortho-nitrophenyl,
and R2 is p-?uoro, m- or p-tri?uoromethyl, m-chloro-p
p-methyl, m-chloro-p-fluoro-, p-ethyl, p-?uoro, m- or
?uoro, p-ethyl, or m-chloro, and when R1 =2,6
p-chloro, p-bromo, m-nitro, or p-COOR3, wherein R3 is
dichlorophenyl, R2 can be p-bromo, and when R1=2
lower alkyl of one to four carbon atoms.
pyridyl, R; can be hydrogen.
Also provided are methods for administration of the
There is further provided by this invention methods
anticonvulsant compositions of this invention to mam
for administration of the anticonvulsant composition to
mals in the treatment of convulsive disorders such as
epilepsy including petit mal and grand mal.
20 mammals including animals and humans.
The triazolines of this invention may be prepared by
There is also provided by this invention certain new

2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or

Z-quinolyl, and R2 is hydrogen, m- or p-trifluoromethyl,

compounds which are useful as anticonvulsant.drugs.

the reaction of diazomethane with Schiff bases as de

These compounds may be characterized by the follow

scribed, for example, by Mustafa, A., (J. Chem. Soc.),
234 (1949), and by Buckley, G. D., (J. Chem. 300.),
1850, (1954). Further methods of preparation involving

ing general formulae:
25

1,3-dipolar cycloaddition reactions are described in the
applicants’ own publications in Kadaba, et al. (J. Org.
Chem., 26, 2331 (1961), by Kadaba in “Tetrahedron,”
22, 2453 (1966), by Kadaba in “Tetrahedron,” 25, 3053
30 (1969) and J. Heterocyclic Chem., 12, 143, (1975). This
reaction proceeds generally in accordance with the

following equation.

Wherein R1 is 4-pyridyl, S-pyridyl, 2-pyridyl, ortho
chlorophenyl, 2,6-dichlorophenyl, or ortho-nitrophe
nyl, and R2 is p-?uoro, p-bromo, m-chloro-p-?uoro, m
or p-tri?uoromethyl, p-ethyl, m-chloro, or hydrogen.

+ CH2N2 %

DESCRIPTION OF PREFERRED
EMBODIMENTS
R2

As indicated above, this invention relates to certain
‘ 1,2,3-triazolines which are useful as anticonvulsants.

R1

N

E 4Nl

The triazolines of this invention are to be named as

A2-l,2,3-triazolines, or as
lH-4,5-dihydro-l,2,3
triazoles. The triazolines of this invention are substi

N

tuted in the 1 and 5 positions by aryl or heterocyclic

A2-l,2,3-Triazolines
groups which may also contain substituents. The triazo 45
line compounds of this invention have potent to moder
In the above equation R1 and R2 are as de?ned above.
ate anticonvulsant activity as antiepileptic drugs in the
Kinetic studies on solvent effects of this reaction
treatment of convulsive disorders such as petit mal
indicate that protic solvents such as water have a gen

(absence seizures) and grand mal (major motor sei

zures).
In one aspect of the invention, it relates to novel

anticonvulsant compositions which comprise as the
active ingredient a compound selected from those of the

following formulae:

50

eral accelerating effect on the reaction and by carrying
out the addition reaction in an aqueous dioxane solution,

high yields of triazolines are produced.
As pointed out, the triazoline compounds and result
ing anticonvulsant compositions of this invention are
55 useful in the treatment of convulsive disorders. The

N

potency of the compounds range from those which are
very potent to those of moderate potency. A series of
triazolines of this invention has been evaluated in Phase
I anticonvulsant screening using two seizure models in
the mouse, the maximal electro-shock seizure (MES)
test and the subcutaneous pentylenetetrazole (Met
razole) seizure threshold (scMet) test. These two meth

ods of seizure provocation reliably elicit well character
ized seizure phenomena (Chen. G., et al. Proc. Soc.
Z-quinolyl, and R2 is hydrogen, m- or p-tri?uoromethyl, 65 Exp. Biol. Med., 87, 334 (1954), and together have been
shown suf?cient to identify all compounds known to
p-methyl, m-chloro-p-?uoro, p-ethyl, p-fluoro, m- or
demonstrate anticonvulsant activity in other tests.
p-chloro, p-bromo, m-nitro, or p-COORg, wherein R3 is
Based on the Phase I screening results, the compound to
lower alkyl of one to four carbon atoms.

Wherein R1 is o-chlorophenyl, o-nitrophenyl, 2,4- or

2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, Z-pyridyl, or

4,689,334
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6

be tested is placed in one of three categories. Those
failing to demonstrate anticonvulsant activity at doses

TABLE l-continued

up to 300 mg/kg are considered inactive. Class 11 com

Anticonvulsant Activity
Group Classi?cation

Compound

pounds show anticonvulsant activity at doses greater
than 100 mg/kg or show activity at 100 mg/kg which is
not reinforced by similar activity at 300 mg/kg. Thus
compounds of class or group II demonstrate anticon

A2-l,2,3-triazoline
As shown in the above table, the most potent com

pounds are compounds 9,10,16 and 17 which are the
four compounds of Class I. In addition, compounds 7

vulsant activity without signs of neurological de?cit,
but do not have signi?cant potency. The Class I com
pounds are those which are most promising as anticon

and 12 in Class II are also effective anticonvulsant com

vulsants. They demonstrate anticonvulsant activity in
either the MES test or the ScMet test, or both at doses

of 100 mg/kg or 30 mg/kg without signs of neurologi
cal de?cit and thus have an estimated protective index
15
of greater than I.
The following table presents the results of these tests

pounds because they give 100% protection at 600 and
300 mg/kg, respectively, without any signs of neurolog
ical de?cit. Thus, these six compounds represent the
preferred embodiments of the anticonvulsant composi
tions of this invention. Compound 9 which is l-(para

chlorophenyl)-5-(4-pyridyl)-A2-1,2,3-triazoline

and

with respect to certain compounds of the present inven
tion. This Table 1 identi?es the speci?c compounds
tested, by chemical name and provides the anticonvul

compound 16 which is 1-(p-tri?uoromethylphenyl)-5

TABLE 1

and the azide-ole?n cycloaddition reaction of the fol

(4-pyridyl)-A2-1,2,3-triazoline are the most preferred
compounds of this invention.
sant activity based on classi?cation in Group I or Group 20 As indicated above while various preparative reac
tions are known for the triazolines of the invention, the
II.

diazo-alkane-imine reaction of the following equation 1

Anticonvulsant Activity
Group Classi?cation

Compound

25

lowing equation 2 are generally preferred for 1,2,3
triazoline synthesis:

ll

1. l-m-tri?uoromethylphenyl

5-(o»chlorophenyl)

A2~1,2,3-triazoline
5-(o-chlorophenyl)
A2»l,2,3-triazoline

2. l-(p-Tri?uoromethylphenyl

II

30

3. l-(p-EthylphenyD

5-(o-chlorophenyl)

A2-l,2,3-triazoline
4. l-(m-Chlorophenyl)

5-(o-nitrophenyl)

A2-l,2,3-triazoline

35

5. l-(m-Nitrophenyl)

5-(2,4-dichlorophenyl)

A2-l,2,3-triazoline
6. l-(p-Bromophcnyl)»

II

5-(2,6-dichlorophenyl)

A2-l,2,3-triazoline
7. l-(Phenyl)-

II

5-(4-pyridyl)

A2-l,2.3-triazoline
5~(4—pyridyl)
A2-1,2,3-triazoline

8. l-(p-EthoxycarbonyD
9. 1~(p-Chlorophenyl)-

I

45

R

5-(4-pyridyl)
.

l-(p-Fluorophenyl)-

ll.

A2-l,2,3-triazoline
l-(p-MethylphenyD

1

N

l

|

N%

N

I

Since Schiff bases (imines) bearing a range of aro
50 matic or heterocyclic substitutents can be readily pre

pared, the CHgNg-imine reaction is particularly suited
for the synthesis of the l,5-substituted triazolines in this
patent application. As pointed out above, this addition is

A2-1,2,3-triazoline
. l-(m-chlorophenyl)

5-(4-pyridyD
.

R]

preferably carried out in aqueous dioxane solutions

A2-l,2,3-triazoline
l-(phenyl)
5-(2-pyridyl)
A2-l,2,3-triazoline

55

according to the applicant’s previous publications. In a
typical preparation, the Schiff base is dissolved in a

cold, freshly prepared solution of CI-IZNZ in wet diox

. l-(p-Chlorophenyl)

ane. The reaction mixture is then allowed to stand at

5-(2-pyridyD

l5°—20° C. for 2-4 days in the case of the reactive anils
and 6-7 days in the case of the slow reactions. At the

A2-1,2,3-triazoline
. l-(m-Nitrophenyl)

5-(2-quinolyl)

A2-l,2,3-triazoline

end of this period, the mixture is cooled and diluted
with water to precipitate the triazoline adduct.

A2-1,2,3-triazoline

from N,N’-nitrosomethylurea in the same manner that

The CHgNz for the reaction is prepared conveniently
. l-(m-tri?uoromethylphenyl)-

5-(4-Pyridyl)

A2-l,2,3-triazoline
. 1—(m-chloro-p-fluorophenyl)

5-(3-PyridyD

I

65 undistilled ethereal solutions are obtained, but using

1,4-dioxane in place of diethyl ether. Dioxane is the
solvent of choice because of its easy miscibility with
water and the ease with which it can be substituted for

4,689,334
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diethyl ether. The CHzNz solution thus obtained con
tains water in suf?cient amounts to catalyze the reaction
and is used immediately.
The Schiff bases are prepared using standard proce

8
TABLE 2-continued
Compound

M. pt. °C.

Yield %

. l-(p-ChlorophenyD

5-(2-pyridyl)
A2-1,2,3-triazoline

dures by heating a mixture of the appropriate adehyde
and amine in ethanol or alternatively by heating the

.

mixture in benzene followed by azeotropic removal of
the water, the latter being a more suitable procedure in

l-(m-NitrophenyD

5-(2-quinolyl)

A2-l,2,3-triazoline
. 1-(p-tri?uoromethylphenyD

difficult cases.

149-150

The anticonvulsant compounds of the present inven
tion may be administered to animals or humans at doses

68-71

42

ranging from about 30 mg/kg up to about 300 mg/kg.
Preferred levels of administration range from about 30
88-91
. l-(m-chloro-p-fluorophenyl)
mg/kg up to 100 mg/kg. The active ingredients or
5-(3-pyridyl)
compounds of this invention may be administered in
A2-l,2,3-triazoline
any desired form by injection or in the oral form. Con
ventional adjuvents and carriers may be employed in
These compounds were identi?ed through their ele
combination with about 0.001 to 2.0 wt.% of the active
mental analyses, characteristic melting point (they de
ingredient. Thus the anticonvulsant compositions of this
invention may be administered in pill form or by injec 20 compose at their melting point with vigorous evolution
of nitrogen), and NMR spectra, which exhibits an ABC
tion. As indicated above, the dosage rate ranges from
pattern in the 4.5 to 5.0 ppm region for the three protons
about 30 mg/kg up to about 300 mg/kg.
at positions 4 and 5.
The following examples are presented to illustrate the
These compounds were then evaluated in accordance
invention but it is not to be considered as limited
with the methods set forth above for anticonvulsant
characteristics. The results are set forth in Table 1
above. As pointed out with respect to Table l, the com

thereto. In the examples and throughout the speci?ca
tion, parts are by weight unless otherwise indicated.
EXAMPLE 1

pounds demonstrate anticonvulsant activity in either

“_ Using the reaction of Equation 1 described above

the MES test or the scMet test or both. Compounds of

'fiinvolving cycloadditions of diazoalkanes to imines

30 Class I demonstrate this activity as doses of 100 mg/kg

f‘(Schiff bases), the following compounds were prepared.

or 30 mg/kg without signs of neurological de?cit and

“In the following Table 2, melting points and yields are
given for new compounds prepared.

thus have an estimated protective index of greater than

TABLE 2
Compound
1. l-m-tri?uoromethylphenyl

1.
35

M. pt. °C.

Yield %

49-51

77

83-86

80

One of the compounds, compound 9 which is l-(para
chloropheny1)-5-(4-pyridyl)A2-1,2,3-triazoline,
was
evaluated for further study to provide additional infor
mation as to its general pro?le of anticonvulsant activ

5-(o-chlorophenyl)

A2-l,2,3-triazoline
2. l-(p-Tri?uoromethylphenyl)

ity.
Thirty minutes after administration, compound 9 of

5-(o-chlorophenyl)

A2-l,2,3-triazoline
3. l-(p-Ethylphenyl)

48

this invention exhibited anti-maximal electroshock

5-(o-chlorophenyl)

(MES) activity at 300 mg/kg and anti-Metrazol activity

A2-l,2,3-triazoline
4. l~(m-Chloropheny1)

90-92

45

5-(o-nitrophenyl)

A2-1,2,3-triazoline
5. l-(m-Nitrophenyl)

5-(2,4-dichlorophenyl)

A2-l,2,3-triazoline
6. l-(p-Bromophenyl)

156

75

5-(2,6—dichlorophenyl)

activity of compound 9 was characterized by the ability
to modify maximal electroshock seizure pattern and to

A2-1,2,3-triazoline
5-(4-pyridy1)

elevate the Metrazol seizure threshold in nontoxic
doses. Accordingly, the compound was subjected to

A2-1,2,3-triazoline
8. l-(p-Ethoxycarbony1)

5-(4-pyridyl)

55

A1-1,2,3-triazoline
9. 1-(p-Ch1orophenyl)

5-(4-PyridyD

A2-l,2,3-triazoline
139-141

72

A2=l,2,3-triazoline

sant activity and toxicity of compound 9 with those of

. l-(p-MethylphenyD

clinically useful antiepileptic drugs.

5-(4-pyridyl)
A2-l,2,3-triazoline
109-110

80

84-85

24

5-(4 pyridyl)

A2-l,2,3-triazoline
. 1-(phenyl)

Phase II Anticonvulsant Quanti?cation in Mice i.p.,
Phase III Toxicity Pro?le in Mice i.p., Phase IV Anti
convulsant Quanti?cation in Mice p.o., Phase V Antiep
ileptic Drug Differentiation in Mice i.p., and Phase VI
Anticonvulsant Quanti?cation in Rats p.o. The results

60 obtained provided the basis to compare the anticonvul

5-(4-pyridyl)

. l-(m-chlorophenyD

at 100 mg/kg. Rotored toxicity was not seen in animals

given up to 300 mg/kg of the test substance. Four hours
after administration, the compound was ineffective by
the MES test (although the tonic extension was slow) at
300 mg/kg; however, anti-Metrazol activity was pres
50 ent at this dose level. Thus, the pro?le of anticonvulsant

7. 1-(Phenyl)

. lv(p~Fluorophenyl)

EXAMPLE 2

In this experiment male albino mice (CF No. 1 strain;
18 to 25 g wt) obtained from Charles Rivers, Wilming
65 ton, Mass, and male albino rats (Sprague Dawley, 100
to 150 g wt) obtained from Simonsen, Gilroy, Calif.,

5-(2-pyridyl)

were used as experimental animals. All animals were

A2-1,2,3-triazoline

allowed free access to both food (S/L Custom LaB

4,689,334
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Diet-7) and water, except when they were removed

normal mouse is placed on a knurled rod one inch in

from their cages for the experimental procedure.
Compound :9 was compared with four prototype

diameter rotating at a speed of six rpm it can maintain its

antiepileptic agents (phenytoin, phenobarbital, ethosux
imide, and valproate). Compound 9 was administered in

cit is indicated by inability of the mouse to maintain its
equilibrium for one minute in each of three trials on this

the requisite volume of 30% polyethylene glycol 400;
whereas phenytoin, phenobarbital, ethosuximide, and

rotating rod. Neurological de?cit in rats is indicated by
ataxia, loss of placing response and muscle tone. Se

valproate were administered in 0.9% sodium chloride
solution. The drugs were administered either orally or

duced by each prototype agent and test substance were

intraperitoneally in a volume of 0.01 ml/g body weight

equilibrium for long periods of time. Neurological de?

condly, the overt signs and symptoms of toxicity in
0

in mice and 0.04 ml/l0 g in rats. All tests were con

ducted at the previously determined time of peak drug
effect. To determine anticonvulsant potency and toxic
ity, groups of at least eight mice or rats were tested with
various doses of the drug until at least four points were

established between the limits of 100% protection or

determined by giving two mice either 1TD50, 2TD50’s,
or 4TD50’s and observing and testing them 10, 20, and
30 minutes and 1, 2, 4, 6, 8, and 24 hours after drug
administration for the onset, intensity, and type of overt

toxicity. These observations also provide preliminary
5

information essential for the subsequent determination
of the HD50 and LDSO. The HD50 represents the me

dian dose at which 50% of animals lose their righting
toxicity and 0% protection or toxicity. The dose of drug
re?ex. The 24-hour LD50 represents the median dose
required to produce the desired endpoint in 50% of
which causes death in 50% of the animals within 24
animals (ED50) in each test, the dose eliciting evidence
of minimal neurological toxicity in 50% of animals 20 hours.
Except for bicuculline, all convulsant drugs (Metra
(TD50), the 95% con?dence interval, the slope of the
zol, picrotoxin, and strychnine) administered to mice
regression line, and the SE. of the slope were then
were dissolved in suf?cient 0.9% sodium chloride solu
tion to make a concentration of 0.85%, 0.032%, and
The pro?le of anticonvulsant activity for each sub 25 0.012%, respectively. Bicuculline was dissolved in 1 ml
of warmed 0.1N HCl with the aid of a micro-mixer and
stance was established by ?ve tests: one electrical and
suf?cient 0.9% sodium chloride solution added to make
four chemical. The electrical test employed was the
a 0.027% solution; the solution was used 15 to 45 min
maximal electroshock seizure pattern test. This test
utes after preparation. Metrazol (3.5%) was adminis
measures the ability of the test drug to abolish the hind
tered to rats in a solution of 0.9% sodium chloride.
limb tonic-extensor component of maximal seizures
All convulsants were administered subcutaneously
induced in mice by 50 mA of current delivered for 0.2

calculated by means of a computer program written by
NINCDS.

seconds or in rats at 150 mA of current delivered for 0.2

into a loose fold of skin on the back of the neck in a

seconds; this amount of current is approximately six
times the threshold and reveals the ability of the test
substance to prevent seizure spread. The four chemical
tests include the subcutaneous Metrazol Seizure

volume of 0.01 ml/g body weight in mice; Metrazol was
injected in a volume of 0.02 ml/ 10 g body weight in

measure the ability of anticonvulsants to afford com

the presence or absence of a seizure. Except for strych
nine, absence of a ?ve-second episode of clonic spasms
(threshold seizure) was taken as protection. In the case

rats. The convulsant drugs were administered at the

previously determined time of peak anticonvulsant ac
tion of the drug under study. Except for picrotoxin
Threshold Test (sc Met Test), Subcutaneous Bicucul
treated animals, the mice (eight animals/group) were
line Seizure Threshold Test (sc Bic Test), subcutaneous
then observed for at least 30 minutes for the presence or
Picrotoxin Seizure Threshold Test (sc Pic Test), and the
subcutaneous Strychnine Seizure Pattern Test (sc 40 absence of a seizure. The animals treated with picro
toxin were observed for periods of 45 to 60 minutes for
Strych Test). Except for the sc Strych Test, these tests

plete protection against threshold seizures induced by

the subcutaneous injection of the CD97 of the convul
sant agent. The $0 Strych Test measures the ability of 45 of strychnine, complete abolition of the hindleg tonic
extension was taken as protection.
the test substance to abolish all tonic components of
The results obtained in Phase II Anticonvulsant
seizures induced by the subcutaneous injection of the
Quanti?cation studies in mice i.p., are shown in Table 3.
CD97 of strychnine. The sc CD97 of Metrazol, bicucul
It may be seen from the table that the times of peak
line, picrotoxin, and strychnine in mice is 85, 2.70, 3.15,
effect (TPE) of the ?ve compounds range from 15 min
and 1.20 mg/kg, respectively; the sc CD97 for Metrazol
utes to 6 hours; except for phenytoin (2 hours by all
in rats is 70 mg/kg.
tests) and compound 9 by the rotorod test (6 hours), the
The pro?le of toxicity for each test drug was estab
TPE’s of the remaining substances vary from 15 min
lished by the following procedures: ?rstly, the minimal
utes to one hour.
neurotoxic dose (TD50) was determined by the rotorod
procedure at the time of peak neurotoxic effect. When a
TABLE 3
PROFILE OF ANTICONVULSANT ACTIVITY OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE
Time
Rotorod
of Test

Substance

(hrs)

TD50

(mg/ kg)

ED50 m /k

MES

and P1

sc Met
4.40‘

Compound

6,5}

9

1132.85

43.53

(97045-133328)

(23575-29753)

(39.00-49.96)

[7.92]

[12.88]

[8.75]
6.89

Phenytoin

2,2,2

26.02‘

257.42

65.46
(52.49-72.11)

9.50
(813-1044)

<0.22
No Protection
up to 300
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TABLE 3-continued
PROFILE OF ANTICONVULSANT ACTIVITY OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE
Time

Rotorod

of Test
Substance

(hrs)

TD50

EDSO (mg/kg! and P1

(mg/kg)

MES

[15.23]

[13.66]

sc Met

69.01

21.78

13.17

(62.84-72.89)
[24.67]

(14.99-25.52)
[14.98]

(5.87—15.93)
[5.93]

440.83
(38309-48534)

No Protection
up to 1000

3.17

Phenobarbital

5,1,1

5.24

< 0.44

Ethosuximide

5,54

3.38

130.35
(110.99-15045)

[18.37]

[10.06]
1.57

valproate

5,5,5

2.87

425.84

271.66

148.59

(36891-45040)
[20.84]

(24697-33789)
[12.83]

(12264-17702)
[11.85]

( ) 95% Con?dence interval

[] Slope, regression line
‘Protective Index (P1) = TDSO/EDSO

3O

35

With respect to anticonvulsant activity, phenobarbital,
the compound of this invention, and valproate had sig
ni?cant anticonvulsant activity in nontoxic doses as

active by the sc Met test range from 2.87 for valproate
to 26.02 for the compound of this invention. Phenobar

. measured by both the maximal electroshock seizures

bital and ethosuximide were also effective by the sc Met

test with P.I.’s of 5.24 and 3.38, respectively.

(MES; EDSO’s 21.78, 257.42, and 271.66 mg/kg, respec
tively) and subcutaneous Metrazol seizure (sc Met;
EDSO’s 13.17, 43.53, and 148.59 mg/kg, respectively)

Phase III, Toxicity Pro?le Studies in Mice given
1TD50, 2TD50’s, and 4TD50’s of Compound 9 intra

tests. In contrast to the above, phenytoin had signi?cant
anti-MES activity (ED50, 9.50 mg/kg) but did not pro
tect against subcutaneous Metrazol seizures. Ethosuxi
mide, on the other hand, was not able to protect against
maximal electroshock seizures but had signi?cant anti
Metrazol activity in nontoxic doses (ED50, 130.35 50

mg/kg).

With regard to minimal neurotoxicity, the compound
of this invention was the least toxic (TD50, 1132.85

peritoneally, were also carried out on the compounds.

The toxicity pro?le induced by Compound 9 was char
acterized by decreased motor activity, ataxia, decreased
respiration and cyanosis. In addition to these symptoms,
one of two animals given 4TD50’s displayed rotorod

toxicity. Both mice given 4TD50’s of Compound 9
were dead 24 hours after drug administration. One of
two animals given 2TD50’s was still ataxic and cyanotic
at the end of 24 hours. A detailed qualitative description

of the pro?le of acute toxicity in mice (i.p.) of Com
pound 9 as well as phenytoin, phenobarbital, ethosuxi
mide, and valproate is shown in Table 4. As shown in
Table 4, the hypnotic dose 50 (HD50) and lethal dose 50
(LDSO) of Compound 9 were 2050.56 and 2132.00

mg/kg); however, 3 of 8 animals given 1300 mg/kg and
5 of 8 animals given 1500 mg/kg were dead 24 hours

after the administration of compound 9. Phenytoin and
phenobarbital were the most toxic with TD50’s of 65.46

and 69.01 mg/kg, respectively. Ethosuximide and val
proate were equitoxic and induced minimal neurologi

mg/kg, respectively. Thus, the HD50 and LD50 for

cal de?cit in 50% of mice at doses of 440.83 and 425.84 60 Compound 9 were signi?cantly higher than those for

mg/kg, respectively.

either phenobarbital (135.45 and 264.70 mg/kg, respec
tively), phenytoin (178.34 and 229.61 mg/kg, respec
tively), or valproate (885.33 and 1104.62 mg/kg, respec

It may also be seen from Table 3 that the protective

indices (TD50/ED50=P.I.) by the MES test range
from < 0.44 for ethosuximide to 6.89 for phenytoin. The

P.I.’s of the remaining three compounds (compound 9
of this invention, phenobarbital, and valproate) are 4.40,
3.17, and 1.57, respectively. The P.I.’s of compounds

65

tively). The HD50 of Compound 9 was higher than that
for ethosuximide (2050.56 vs 850.61 mg/kg), whereas
the LD50’s were no signi?cantly different (2132.00 vs

1752.23 mg/kg).

4,689,334
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TABLE 4
PROFILE OF ACUTE NEUROTOXICITY
OF INTRAPERITONEALLY ADMINISTERED NO. 9 AND SOME PROTOTYPE
ANTIEPILEPTIC DRUGS IN MICE

Pro?le of Acute Toxicity, Mice i.p.
Name

Compound 9

l X TDSO

2 X TDSO

4 X TD50

(1133 mg/kg) Both animals

(2266 mg/kg) Both

were ataxic beginning at 10
min. One animal had decreased
motor activity at 20 min and
both had decreased motor

animals were ataxic

(4532 mg/kg) Both animals had
ataxia and decreased respira-

activity and respiration with
cyanosis at 2 hrs. Both
appeared normal at 24 hrs.

HD50
LDSO'
(mg/kg)

2050.56
(l59l.47—3228.68)

beginning at 10 min.

tion beginning at 10 min. One

They exhibited decreased
respiration with
cyanosis beginning at

animal had decreased motor

213290

[4.27]

activity and rotorod toxicity

(166511436310)
[445]

30 min and decreased motor

with cyanosis at 10 min. The
other animal had decreased

activity beginning at 2 hrs.
One animal appeared

animals were dead at 24 hrs.

motor activity at 2 hrs. Both

normal at 24 hrs
while the other remained

ataxic and cyanotic at 24 hrs.

Phenytoin

quent grooming, nervous be
havior, and straub tail,

(130 mg/kg) Mild ataxia,
periods of sedation, spasms of
arching, rolling, straub tail,
ptosis, and respiratory de

animals were not toxic by the
rotorod test.

(65 mg/kg) Increased motor

activity, slight ataxia, fre

Phenobarbital

(260 mg/kg) Toxic manifestations identical to 2 X TD50. At

178.34
(15293-19545)

1 hr, righting re?ex absent,
longer periods of sedation,

[14.03]
229m

pression. Later, spasms re
duced and sedation increased.

and spasms reduced to head

(216_44_259_10)

twisting and uncoordinated

[15.39]

At 24 hrs, toxicity present,
other symptoms less

movements; respiratory de
pression continued, mice dead

pronounced.

at 24 hours.

(70 mg/kg) Ataxia with

(140 mg/kg) Ataxia with in

increased motor

creased motor activity follow
ed by loss of righting re?ex,

(280 mg/kg) Ataxia with increased motor activity followed by loss of righting re?ex,
tremors, re?ex scratching,

135.45
(1 l4.90-l77.42)
[8.41]

(2415543552)
[15,95]

activity followed
by sedation and ptosis with
one of two animals toxic by
the rotorod test up to 4 hrs.

tremors, re?ex scratching,

respiratory depression. Both

ptosis, sedation, anesthesia
with analgesia and respiratory

mice regained their righting

depression. Both animals

re?ex at 2 hrs and one of two

was still toxic by the rotorod

became cold to touch and
cyanotic with increased res

test at 8 hrs.

piratory depression; death

ptosis, sedation and some

264_7Q

occurred at approximately 3
and 6 hrs.

Ethosuccimide

(440 mg/kg) Uncoordinated

(880 mg/kg) Uncoordinated

(1760 mg/kg) Uncoordinated
motor activity, respiratory

850.61
(75l.l9-917.93)

motor activity, re?ex scratch

motor activity, re?ex scratch

ing, respiratory depression,

ing, loss or’ righting re?ex

depression, hypnosis and

[16.43]

ataxia.

at 4 mins but regained in 20

anesthesia followed at later

175213

mins, hypnosis followed at
later time intervals by seda

time intervals by cyanosis

(160102436664)

and death at 24 hrs.

[1435]

tion, ataxia, ptosis; vasodila
tion and diarrhea.

Valproate

(400 mg/kg) Mild ataxia, with

(800 mg/kg) Ataxia, with both

one of two mice toxic by the

animals toxic by the rotorod
test, normal respiration and

rotorod test. Appeared
normal at the end of 4 hrs.

(1600 mg/kg) Both
animals died.
(At 3 X TDSO there was respira~

885.53
(82086-95704)
[12.46]

some sedation. Both animals

tory depression, ptosis, hyp-

1104,62

appeared normal at 4 hrs.

nosis but no analgesia. These

(1021.54-1253.66)
[11.41]

animals were dead at 4 hrs.)

‘24-hour period

The anticonvulsant activity and minimal neurotoxic
dose (TDSO) upon oral administration were determined

(ED50, 9.04 mg/kg), Whereas valproate was the least
Mice p.o. The TPE of Compound 9 after oral adminis 55 potent (ED50, 664.80 mg/kg). Compared to phenytoin,
phenobarbital was somewhat less potent by the MES
tration was one-half hour by the anticonvulsant tests; 24
test (ED50, 20.09 mg/kg). The test Compound 9, on the
hours was used as the TPE by the rotorod test. The
other hand, was l/ 15 and 1/32 as potent as phenobarbi
TPE by the rotorod test was signi?cantly different from
tal and phenytoin, respectively, with an EDSO of 290.72
that obtained after intraperitoneal administration of test
mg/kg. When evaluated by the subcutaneous Metrazol
Compound 9 (24 hours and six hours, respectively).
threshold test after oral administration, phenobarbital
Except for valproate, the four prototype agents exhib
was the most potent (ED50, 12.59 mg/kg) and valpro
ited TPE’s that were probably not signi?cantly differ
ate was the least potent (ED50, 388.31 mg/kg). The
ent from those observed after the intraperitoneal admin

by Phase IV studies, Anticonvulsant Quanti?cation in

other two compounds (Compound 9 and ethosuximide)
istration of these agents. Valproate had a TPE of one to
two hours after oral administration vs one-fourth hour 65 were equally potent by the scMet test with EDSO’s of

after intraperitoneal administration.
With respect to anticonvulsant activity as measured
by the MES test, phenytoin was again the most potent

152.56 and 192.71 mg/kg, respectively.
By the oral route of administration in mice, cthosuxi
mide and valproate were essentially equitoxic (TD50’s,

15
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879.21, and 1264.39 mg/kg, respectively). Phenytoin

Compound 9 and valproate were the least potent

and phenobarbital were the most toxic with quite simi~

(EDSO’s, 265.76 and 489.54 mg/kg, respectively). The

ED50 of phenytoin by this test was 29.82 mg/kg. When
compared on the basis of the sc Met test, phenobarbital
pound 9 was somewhat more toxic than ethosuximide
with a TD50 of 704.92 mg/kg; however, several deaths 5 was the most potent (ED50, 11.55 mg/kg) and Com
occurred within the dose-range selected for the rotorod
pound 9 and valproate were the least potent (EDSO’s,

lar TDSO’s (86.71 and 96.78 mg/kg, respectively). Com

278.13 and 179.92 mg/kg, respectively). Ethosuximide

regression line (600 and 800 mg/kg, 1 of 8 died; 700 and
1000 mg/kg, 6 and 4 of 8 died).

was somewhat less potent than phenobarbital by this

The R1. for Compound 9 is 2.42 by the MES test,
whereas the P.I.’s for phenytoin, phenobarbital, etho

test with an ED50 of 53.97 mg/kg.

suximide, and valproate are 9.59, 4.82, <0.44, and 1.90,
respectively. The R1. for Compound 9 by the scMet
test is 4.62; whereas those for phenytoin, phenobarbital,
ethosuximide, and valproate are <0.29, 7.69, 4.56, and
3.26, respectively. Thus, the R1. for the Compound 9

most toxic (61.09 mg/kg) and ethosuximide and phenyt
oin the least toxic (TDSO’s, 1012.31 and >3000 mg/kg,

With regard to neurotoxicity, phenobarbital was the

respectively). Valproate and Compound 9 were one
?fth to one-sixth as toxic as phenobarbital with TDSO’s

of 280.26 mg/kg and 393.74 mg/kg, respectively.

substance by the MES test compares very favorably

In summary of the above results, for Compound 9 and

with the PI for valproate (2.42 and 1.90, respectively),

the four prototype agents after intraperitoneal adminis

whereas the R1. for Compound 9 by the scMet test

(4.62) is higher than that for either ethosuximide (4.56)
or valproate (3.26).
The results obtained in Phase V evaluation, Antiepi
leptic Drug Differentiation in Mice, indicated that the
pro?le of anticonvulsant activity of Compound 9 is

tration in mice and oral administration in mice and rats,
it may be stated that, in terms of the pro?le of anticon
20 vulsant activity, Compound 9 is somewhat similar to

that for phenobarbital and valproate. Unlike phenobar
bital and valproate, Compound 9 is ineffective after i.p.
administration in mice by the sc Strych test, whereas

phenobarbital is effective in toxic doses and valproate is

characterized by its effectiveness by the sc Bic and sc

Met tests and its lesser effectiveness by the sc Pic test. 25 effective in nontoxic doses by this test. In terms of roto

Thus, its pro?le resembled that of phenobarbital and

rod toxicity, Compound 9 is only one-third as toxic as

valproate to a certain extent; all three were effective
against sc Met, sc Bio, and so Pic in nontoxic doses. In
contrast to Compound 9 which was not effective
-’ against sc Strych, phenobarbital and valproate were 30

ethosuximide and valproate in this species. After oral
administration, Compound 9 is signi?cantly more neu
rotoxic in rats than it is in mice; there is no signi?cant
difference in the anticonvulsant potency of this sub

.il'effective against strychnine; valproate in nontoxic

stance by the MES and so Met tests in the two species.

“doses, whereas phenobarbital had to be given in toxic
‘doses in order to protect against this chemical convul

higher doses is absorbed only to a limited extent from

sant. Phenytoin, on the other hand, was ineffective

It should be noted that phenytoin administered orally in
the gastrointestinal tract of rats. Consequently, no mini

against Metrazol, bicuculline, and picrotoxin and was
only capable of providing protection in 50% of animals

35 mal neurotoxicity was observed in this species even in

compares favorably with those for phenobarbital, etho
suximide, and valproate.

45 re?ex tests range from one-fourth to one hour. This

doses up to 3000 mg/kg.
"given strychnine. Ethosuximide was effective by the sc
The quantitative toxicity pro?les after intraperitoneal
administration of Compound 9 and the four prototype
"Met, sc Bic, and so Pic tests, and only protected a maxi
agents in mice are summarized in the following Table 5.
:i; mum of 62% of animals by the sc Strych test. However,
"ethosuximide had to be given in toxic doses to protect 40 It may be seen that the time of peak toxicity for Com
against sc Bic seizures. It should also be noted that the
pound 9 by the rotorod and righting re?ex tests are 6
"I. P.I.’s for Compound 9 against sc Met and sc Bic are ?ve
and 24 hours, respectively, whereas those for phenytoin
and ?fty times higher, respectively, than those for phe
are 2 and 12 hours, respectively. The TPE for the other
three prototype agents by the rotorod and righting
nobarbital; the P.I. for Compound 9 by the sc Pic test

table also shows that the LD50/HD50 and
LDSO/I‘D50 ratios for Compound 9 are 1.04 and 1.88,
Rats p.o., it was found. that the TPE for Compound 9 in
respectively. Thus, the ratios between either the mini
this species after oral administration was six hours by
mal toxic dose and the 24-hour lethal dose or the loss of
the toxicity, MES, and sc Met tests. The TPE of the 50 righting re?ex dose and the 24-hour lethal dose for
other four compounds ranged from one-half hour for
Compound 9 are lower than those for any of the four
valproate to ?ve hours for phenobarbital.
candidate substances; hence, it would appear that the
With respect to anticonvulsant activity, after oral
margin between the minimal toxic dose and the 24-hour
lethal dose is probably not satisfactory.
administration in rats, phenobarbital was the most po
tent by the MES test (ED50, 9.14 mg/kg), Whereas
TABLE 5

In Phase VI studies, Anticonvulsant Quanti?cation in

QUANTITATIVE TOXICITY PROFILE OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE
Time

Substance

of Test
(hrs)

Lethality

Dose 50 (mg/kg)
Righting Re?ex

Rotorod

1.04‘

Compound 9

24,24,6

2132.00

2050.56

1.88‘

1132.85

(1666.1 1-3368. 10)

(159l.47-3228.68)

(97045-133328)

[4.45]

[4.27]

[7.92]
1.29

Phenytoin

24,12,2

3.51

229.61

178.34

65.46

(21644-25910)

(15293-19545)

(52.49-12.11)
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TABLE 5-continued
QUANTITATIVE TOXICITY PROFILE OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE
Time
of Test
Dose 50 (mg/kg)

Substance

(hrs)

Lethality

Righting Re?ex

Rotorod

[15.89]

[14.03]

[15.23]
1.95

Phenobarbital 24,1,1

3.84

264.70

135.45

69.01

(24155-28552)
[15.95]

(11490-17742)
[8.41]

(62.84-72.89)
[24.67]

2.06

Ethosuximide 24%,;

1752.23

(160702486664)
[14.75]

3.98

850.61

440.83

(751.l9—917.93)
[16.43]

(38309-48534)
[18.37]

1.25

valproate

24,],1

1104.62

(1021.54—1253.66)
[11.41]

2.59

885.53

425.84

(82086-94704)
[12.46]

(36891-45040)
[20.84]

( ) 95% Con?dence interval

[ ] Slope, regression line
‘Ratio LDSO/l-IDSO or LDSO/T D50

‘In conducting these tests, it was noted that Com

pound 9 is very insoluble and difficult to inject. Conse
quently, it is necessary to administer the high doses

required for the righting re?ex and 24-hour lethality

25

tests in mice in double the volume. In view of this fact,
additional studies were done to determine the effect of
this double volume on the time of peak effect of the test
substance. These studies indicated that the TPE may

less than 4 for adequate absorption. In mice the oral
TD50/i.p. TD50 and oral ED50/i.p. ED50 ratios for
actually be between 12 and 20 hours. For example, after 30 Compound 9 are 0.62, 1.13 and 3.50, by the rotorod,
MES, and sc Met tests, respectively, which suggests
the intraperitoneal injection of 1132 mg/kg in mice, 2, 4,
that the test Compound 9 is adequately absorbed in mice
5, 4, and 3 of 8 animals were toxic by the rotorod test 6,
after oral administration.
12, 18, 20, and 24 hours, respectively, after administra
For a candidate antiepileptic substance to be useful in
tion of the test substance. Moreover, I, 3, and 4 of the 8
the
treatment of seizure disorders, its experimental pro
mice were dead at 20, 40, and 46 hours, respectively.
file of action should compare favorably with that of
Examination of the peritoneal cavity of these animals
revealed an unevacuated stomach that was approxi

clinically useful antiepileptic drugs. Such a comparison

mately three times normal size; an empty, ?accid small

should include not only the anticonvulsant ef?cacy
(ED50), but also the selectivity of toxic and anticonvul
sant effects (slope of the dose-effect regression line),

intestine; and a vermiform appendix markedly enlarged
from flatus. Rats given 400 mg/kg of the test substance
either orally or intraperitoneally presented similar but
somewhat milder gastrointestinal symptoms. This cur
sory gross examination suggests there may be some
relation between these gross abnormalities and the onset

of toxic symptoms and death. Accordingly, additional
pharmacokinetic and pharmacodynamic studies will be

toxicity (LDSO, HDSO, and TDSO), protective indices

(TDSO/EDSO), safety ratios (TD3/ED97), absorption
characteristics (oral ED50/i.p. ED50 and oral

TD50/i.p. TDSO) and the margin of safety (single dose
?ve-day LD50/ED50). An analysis of the data for

Compound 9, phenobarbital, ethosuximide, and valpro

done in order to reveal mechanisms that may contribute

ate reveals that Compound 9 compares very favorably

to the long TPE for neurotoxicity and the abnormally

with the prototype agents. Moreover, the analysis also

shows the relative merits and the disadvantages of
low ratio between the minimal-toxic dose and the 24
50 Compound 9 compared to phenobarbital and valproate.
hour lethal dose.
The merits of the compound are the high P.I.’s derived
The effect of slope on the safety ratio (TD3/ED97) of
from the sc Met and so Bic tests, the high safety ratios
Compound 9, phenobarbital and valproate indicates

that after the intraperitoneal administration of nontoxic
doses, the test substance (Compound 9) will protect

in mice (TD3/ED97; MES, 1.13; sc Met, 3.44) and the
high 24-hour LDSO/EDSO safety ratio by the sc Met

only in mice subjected to the MES test. In this regard,
Compound 9 resembles phenobarbital more closely
than it does valproate. Moreover, it should be noted
that Compound 9 and the prototype agents used for
comparison of the safety ratios do not provide 97%
protection by the MES and so Met tests in nontoxic

LDSO/HDSO and 24-hour LD50/TD50).

97% of mice subjected to either the MES or sc MET 55 test. The disadvantages are related to a lack of selectiv
ity (?at regression lines) by the 24-hour lethality and $0
test. After oral administration of the test substance in
Pic tests and the unfavorable ratios (24-hour
nontoxic doses, the same level of protection is obtained

doses after oral administration in rats.

I

For a candidate drug to be useful in man, it should be
adequately absorbed after oral administration. The ex
tent of oral absorption can be determined from the ratio
of the oral ED50/i.p. ED50, and should be equal to or

The invention has been described herein with refer
ence to certain preferred embodiments. However, as
obvious variations thereon will become apparent to
those skilled in the art, the invention is not to be consid
ered as limited thereto.
I claim:

1. An anticonvulsant composition comprising as the
active ingredient an anticonvulsive effective amount of
a compound selected from the group consisting of those
of the formulae:

19

4,689,334
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6. A composition according to claim 1 wherein R1 is
2,4-dichlorophenyl and R2 is meta-nitro.
7. A composition according to claim 1 wherein R1 is

2,6-dichlorophenyl and R2 is para-bromo.
8. An anticonvulsant composition comprising, an
anticonvulsant effective amount of the active ingredi
N

ent,

l-(m-chloro-p-?uorophenyl)-5-(3-pyridyl)-A2

1,2,3-triazoline and a pharmaceutically acceptable car

wherein R1 is o-chlorophenyl, o-nitrophenyl, 2, 4- or
2,6-dichlorophenyl, or 2-quinolyl, and R2 is hydrogen,

men

9. A composition according to claim 8 wherein a
sufficient amount of the active ingredient is contained in
said composition to provide a dosage amount ranging
from about 30 mg/kg to 300 mg/kg.
10. A composition according to claim 1 wherein R1 is

m- or p-trifluoromethyl, p—methyl, p-ethyl, m- or p

chloro, m-nitro, p-bromo, p-?uoro or p-COOR3
wherein R3 is lower alkyl or 1 to 4 carbon atoms, and a

pharmaceutically acceptable carrier.

15

2-quinolyl and R2 is m-nitro.

2. A composition according to claim 1 wherein R1 is

11. A method for the treatment of convulsive disor
ders in mammals which comprises administration to a
mammal of an effective dosage amount of a composition
according to claim 1 wherein R1 is
of claim 1.
and R2 is para-tri?uoromethyl.
20
12. A method for the treatment of convulsive disor
according to claim 1 wherein R1 is
ders in mammals which comprises administration to a
and R2 is para-ethyl.
mammal of an effective dosage amount of a composition
according to claim 1 wherein R1 is
of claim 9.

ortho-chlorophenyl and R2 is meta-tri?uoromethyl.
3. A composition

ortho-chlorophenyl
4. A composition

ortho-chlorophenyl

5. A composition
ortho-nitrophenyl and R2 is meta-chloro.

i
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